Ultragenyx Pharmaceutical (RARE) Short Interest Ratio & Short Volume → Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes) (Ad) Free RARE Stock Alerts $40.58 -0.95 (-2.29%) (As of 04:27 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Ultragenyx Pharmaceutical Short Interest DataCurrent Short Interest4,650,000 sharesPrevious Short Interest4,380,000 sharesChange Vs. Previous Month+6.16%Dollar Volume Sold Short$197.81 millionShort Interest Ratio6.3 Days to CoverLast Record DateApril 30, 2024Outstanding Shares83,130,000 sharesPercentage of Shares Shorted5.59%Today's Trading Volume589,691 sharesAverage Trading Volume762,338 sharesToday's Volume Vs. Average77% Short Selling Ultragenyx Pharmaceutical ? Sign up to receive the latest short interest report for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRARE Short Interest Over TimeRARE Days to Cover Over TimeRARE Percentage of Float Shorted Over Time Ad Stansberry ResearchEverybody laughed when he recommended Netflix"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. Ultragenyx Pharmaceutical Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20244,650,000 shares $197.81 million +6.2%N/A6.3 $42.54 4/15/20244,380,000 shares $187.77 million +11.7%N/A6.3 $42.87 3/31/20243,920,000 shares $183.02 million +3.7%N/A5.3 $46.69 3/15/20243,780,000 shares $179.06 million -2.3%N/A5 $47.37 2/29/20243,870,000 shares $200.16 million +8.7%N/A4.9 $51.72 2/15/20243,560,000 shares $164.69 million +4.4%N/A4.6 $46.26 Get the Latest News and Ratings for RARE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 1/31/20243,410,000 shares $150.42 million -17.2%N/A4.3 $44.11 1/15/20244,120,000 shares $188.28 million +1.5%N/A4.4 $45.70 12/31/20234,060,000 shares $194.15 million +21.6%N/A4.1 $47.82 12/15/20233,340,000 shares $153.54 million +3.1%N/A3.4 $45.97 11/30/20233,240,000 shares $125.87 million -7.4%N/A3.4 $38.85 11/15/20233,500,000 shares $136.78 million -15.9%N/A3.8 $39.08 10/31/20234,160,000 shares $147.26 million +24.6%N/A4.6 $35.40 10/15/20233,340,000 shares $112.12 million -15.0%5.0%4 $33.57 9/30/20233,930,000 shares $140.10 million +15.6%5.9%6.3 $35.65 9/15/20233,400,000 shares $128.11 million -1.5%5.1%6 $37.68 8/31/20233,450,000 shares $126.93 million -1.7%5.2%6.2 $36.79 8/15/20233,510,000 shares $134.75 million -1.1%5.3%6.2 $38.39 7/31/20233,550,000 shares $153.08 million -10.4%5.4%5.9 $43.12 7/15/20233,960,000 shares $174.95 million +6.5%6.0%6.4 $44.18 6/30/20233,720,000 shares $171.60 million +22.0%5.7%5.7 $46.13 6/15/20233,050,000 shares $149.02 million -4.1%4.7%4.5 $48.86 5/31/20233,180,000 shares $156.96 million -8.9%4.9%4.8 $49.36 5/15/20233,490,000 shares $171.08 million +17.1%5.3%5.5 $49.02 4/30/20232,980,000 shares $130.14 million +4.2%4.6%4.9 $43.67 4/15/20232,860,000 shares $109.25 million -8.0%4.4%4.8 $38.20 3/31/20233,110,000 shares $124.71 million +4.4%4.8%5.2 $40.10 3/15/20232,980,000 shares $121.38 million -3.3%4.6%5 $40.73 2/28/20233,080,000 shares $137.03 million -6.4%4.7%4.8 $44.49 2/15/20233,290,000 shares $145.45 million -3.2%5.1%4.8 $44.21 1/31/20233,400,000 shares $154.12 million -4.8%5.2%4.6 $45.33 1/15/20233,570,000 shares $155.47 million +6.3%5.5%4.7 $43.55 12/30/20223,360,000 shares $155.67 million -1.2%5.2%4.3 $46.33 12/15/20223,400,000 shares $154.94 million +14.1%5.2%4.2 $45.57 11/30/20222,980,000 shares $108.17 million -1.3%4.6%3.8 $36.30 11/15/20223,020,000 shares $107.09 million +2.0%4.7%4.1 $35.46 10/31/20222,960,000 shares $119.76 million -8.6%4.6%4.1 $40.46 10/15/20223,240,000 shares $120.07 million +5.9%5.0%4.5 $37.06 9/30/20223,060,000 shares $126.71 million -1.9%4.7%4.1 $41.41 9/15/20223,120,000 shares $147.51 million +6.5%4.8%4.5 $47.28Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. 8/31/20222,930,000 shares $139.73 million -3.9%4.5%4.2 $47.69 8/15/20223,050,000 shares $156.16 million +7.4%4.7%4.4 $51.20 7/31/20222,840,000 shares $151.32 million -5.0%4.4%4.1 $53.28 7/15/20222,990,000 shares $193.60 million +3.5%4.6%4.6 $64.75 6/30/20222,890,000 shares $172.42 million +7.0%4.5%5.1 $59.66 6/15/20222,700,000 shares $136.92 million +0.4%4.2%4.9 $50.71 5/31/20222,690,000 shares $126.16 million -10.9%4.2%5.2 $46.90 5/15/20223,020,000 shares $155.44 million -1.3%4.7%6.2 $51.47 4/30/20223,060,000 shares $216.31 million +5.9%4.8%6.9 $70.69 4/15/20222,890,000 shares $246.81 million +2.5%4.5%6.7 $85.40 3/31/20222,820,000 shares $204.79 million -3.8%4.4%6.6 $72.62 3/15/20222,930,000 shares $186.61 million -3.3%4.6%7.1 $63.69 2/28/20223,030,000 shares $203.98 million -8.5%4.7%7.3 $67.32 2/15/20223,310,000 shares $243.45 million -4.9%5.2%7.6 $73.55 1/31/20223,480,000 shares $243.36 million -0.3%5.5%8.5 $69.93 1/15/20223,490,000 shares $251.45 million +0.6%5.5%8.5 $72.05 12/31/20213,470,000 shares $291.79 million -11.5%5.5%8.2 $84.09 12/15/20213,920,000 shares $325.56 million -1.3%6.2%9.2 $83.05 11/30/20213,970,000 shares $298.66 million -2.7%6.3%9.5 $75.23 11/15/20214,080,000 shares $328.60 million +10.3%6.5%10.6 $80.54 10/29/20213,700,000 shares $310.50 million -3.9%5.9%9.1 $83.92 10/15/20213,850,000 shares $308 million -4.0%6.1%9.3 $80.00 9/30/20214,010,000 shares $361.66 million +3.9%6.4%9.7 $90.19 9/15/20213,860,000 shares $374.42 million -4.0%6.1%7 $97.00 8/31/20214,020,000 shares $387.09 million -0.7%6.4%6.7 $96.29 8/13/20214,050,000 shares $375.60 million -0.5%6.4%6.6 $92.74 7/30/20214,070,000 shares $324.91 million +3.0%6.5%6.6 $79.83 7/15/20213,950,000 shares $334.76 million +4.5%6.3%6.5 $84.75 6/30/20213,780,000 shares $360.42 million -23.6%6.0%6.3 $95.35 6/15/20214,950,000 shares $495.20 million -2.6%7.8%10.4 $100.04 5/28/20215,080,000 shares $516.69 million -1.0%8.0%11.6 $101.71 5/14/20215,130,000 shares $547.42 million -6.0%N/A12.1 $106.71 4/30/20215,460,000 shares $619.76 million +1.1%N/A12.4 $113.51 4/15/20215,400,000 shares $583.04 million -2.0%N/A13.1 $107.97 3/31/20215,510,000 shares $617.45 million -0.5%N/A12.1 $112.06 3/15/20215,540,000 shares $703.30 million -5.5%N/A11.2 $126.95 2/26/20215,860,000 shares $798.43 million +10.4%N/A11.6 $136.25 2/12/20215,310,000 shares $864.36 million -0.4%N/A10.9 $162.78 1/29/20215,330,000 shares $749.40 million -3.3%N/A11.3 $140.60 1/15/20215,510,000 shares $770.68 million -5.3%N/A10.1 $139.87 12/31/20205,820,000 shares $840.23 million -7.6%N/A11.3 $144.37 12/15/20206,300,000 shares $965.29 million -4.1%N/A14.2 $153.22 11/30/20206,570,000 shares $804.30 million -4.0%N/A15.4 $122.42 11/15/20206,840,000 shares $801.78 million -3.3%N/A16.4 $117.22 10/30/20207,070,000 shares $671.65 million -4.3%N/A17.4 $95.00 10/15/20207,390,000 shares $684.98 million +5.4%13.2%22.3 $92.69 9/30/20207,010,000 shares $576.15 million +1.7%12.5%20.3 $82.19 9/15/20206,890,000 shares $559.67 million +1.6%12.3%16.9 $81.23 8/31/20206,780,000 shares $576.71 million -0.9%12.1%15.7 $85.06 8/14/20206,840,000 shares $582.15 million -14.7%12.2%15.2 $85.11Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. 7/31/20208,020,000 shares $626.84 million No Change14.3%16.1 $78.16 7/15/20208,020,000 shares $684.99 million +4.6%14.5%15.2 $85.41 6/30/20207,670,000 shares $564.97 million +3.4%13.7%13.7 $73.66 6/15/20207,420,000 shares $513.54 million -2.2%13.3%13.5 $69.21 5/29/20207,590,000 shares $520.60 million +0.8%13.6%13 $68.59 5/15/20207,530,000 shares $536.81 million +1.4%13.5%12.7 $71.29 4/30/20207,430,000 shares $448.99 million No Change13.3%13.1 $60.43 4/15/20207,430,000 shares $416.90 million -1.1%13.5%13.7 $56.11 3/31/20207,510,000 shares $497.39 million +8.1%13.6%12.5 $66.23 3/13/20206,949,400 shares $364.84 million +6.9%12.8%14.5 $52.50 2/28/20206,500,000 shares $247.85 million +1.4%12.0%12.7 $38.13 2/14/20206,410,000 shares $315.24 million -4.2%11.8%11.9 $49.18 1/31/20206,690,000 shares $372.70 million +4.0%12.5%12.2 $55.71 1/15/20206,430,000 shares $396.09 million -1.1%12.0%11.3 $61.60 12/31/20196,500,000 shares $370.31 million +6.2%12.1%11.7 $56.97 RARE Short Interest - Frequently Asked Questions What is Ultragenyx Pharmaceutical's current short interest? Short interest is the volume of Ultragenyx Pharmaceutical shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 4,650,000 shares of RARE short. Learn More on Ultragenyx Pharmaceutical's current short interest. What is a good short interest ratio for Ultragenyx Pharmaceutical? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RARE shares currently have a short interest ratio of 6.0. Learn More on Ultragenyx Pharmaceutical's short interest ratio. Which institutional investors are shorting Ultragenyx Pharmaceutical? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ultragenyx Pharmaceutical: Walleye Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Ultragenyx Pharmaceutical's short interest increasing or decreasing? Ultragenyx Pharmaceutical saw a increase in short interest in April. As of April 30th, there was short interest totaling 4,650,000 shares, an increase of 6.2% from the previous total of 4,380,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Ultragenyx Pharmaceutical's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Ultragenyx Pharmaceutical: Biohaven Ltd. (10.91%), Summit Therapeutics Inc. (28.19%), Prestige Consumer Healthcare Inc. (3.79%), IDEAYA Biosciences, Inc. (16.17%), Axsome Therapeutics, Inc. (16.23%), HUTCHMED (China) Limited (0.26%), Xenon Pharmaceuticals Inc. (3.70%), Insmed Incorporated (5.74%), Crinetics Pharmaceuticals, Inc. (6.23%), Corcept Therapeutics Incorporated (22.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Ultragenyx Pharmaceutical stock? Short selling RARE is an investing strategy that aims to generate trading profit from Ultragenyx Pharmaceutical as its price is falling. RARE shares are trading down $0.95 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ultragenyx Pharmaceutical? A short squeeze for Ultragenyx Pharmaceutical occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RARE, which in turn drives the price of the stock up even further. How often is Ultragenyx Pharmaceutical's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RARE, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: BHVN Short Interest Data SMMT Short Interest Data PBH Short Interest Data IDYA Short Interest Data AXSM Short Interest Data HCM Short Interest Data XENE Short Interest Data INSM Short Interest Data CRNX Short Interest Data CORT Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RARE) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals"The Biggest Drug Ever" Is ComingBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace